Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Compass Therapeutics (Nasdaq: CMPX) presented preclinical data on CTX-10726, a tetravalent bispecific antibody targeting PD-1 and VEGF-A, at the 40th SITC Annual Meeting on November 7, 2025.
Key findings: CTX-10726 showed high-affinity binding to human and cynomolgus VEGF-A and PD-1, dose-dependent blockade of VEGF-A/VEGFR2 and PD-1/PD-L1 interactions, and potent IFN-γ immunomodulatory activity in vitro. In vivo, CTX-10726 produced tumor elimination in multiple models and demonstrated superior anti-tumor activity versus comparator antibodies including ivonescimab and bevacizumab in xenograft and knock-in mouse models. The company said an IND submission is on track for Q4 2025. Presentation materials will be posted on the company website after the meeting.
Compass Therapeutics (Nasdaq: CMPX) ha presentato dati preclinici su CTX-10726, un anticorpo bispecifico tetravalente mirato a PD-1 e VEGF-A, al 40° SITC Annual Meeting il 7 novembre 2025.
Principali risultati: CTX-10726 ha mostrato un legame ad alta affinità sia con VEGF-A sia con PD-1 umano e cynomolgus, blocco dose-dipendente delle interazioni VEGF-A/VEGFR2 e PD-1/PD-L1, e potente attività immunomodulatoria IFN-γ in vitro. In vivo, CTX-10726 ha prodotto eliminazione del tumore in molteplici modelli e ha dimostrato un’attività antitumorale superiore rispetto ad anticorpi di confronto, tra cui ivonescimab e bevacizumab, in modelli xenograft e knock-in su topo. L’azienda ha dichiarato che una presentazione IND è prevista per il Q4 2025. Il materiale della presentazione sarà pubblicato sul sito web dell’azienda dopo l’incontro.
Compass Therapeutics (Nasdaq: CMPX) presentó datos preclínicos sobre CTX-10726, un anticuerpo bispecifico tetravalente que apunta a PD-1 y VEGF-A, en la 40.ª Reunión Anual SITC el 7 de noviembre de 2025.
Hallazgos clave: CTX-10726 mostró alta afinidad por VEGF-A y PD-1 tanto en humanos como en cynomolgus, bloqueo dependiente de la dosis de las interacciones VEGF-A/VEGFR2 y PD-1/PD-L1, y potente actividad inmunomoduladora de IFN-γ in vitro. In vivo, CTX-10726 produjo la eliminación de tumores en múltiples modelos y demostró una actividad antitumoral superior frente a anticuerpos comparadores, incluidos ivonescimab y bevacizumab, en modelos xenograft y de ratón knock-in. La empresa indicó que una presentación de IND está en camino para el Q4 de 2025. El material de la presentación se publicará en el sitio web de la empresa después de la reunión.
Compass Therapeutics (나스닥: CMPX)가 CTX-10726에 대한 전임상 데이터를 PD-1과 VEGF-A를 표적으로 하는 사가만능 빌리스페시픽 항체로서 40th SITC 연례 회의에서 2025년 11월 7일 발표했습니다.
주요 결과: CTX-10726은 인간 및 Cynomolgus의 VEGF-A와 PD-1에 대한 고친화성을 보였고, VEGF-A/VEGFR2 및 PD-1/PD-L1 상호작용의 용량 의존적 차단, 그리고 In Vitro에서 IFN-γ의 강력한 면역조절 활성을 나타냈습니다. In vivo에서 CTX-10726은 다수의 모델에서 종양 제거를 보였고, 이종 이식 및 노크인 마우스 모델에서 ivonescimab 및 bevacizumab를 포함한 비교 항체에 비해 우수한 항종양 활성을 입증했습니다. 회사는 IND 제출이 2025년 4분기에 예정되어 있다고 밝혔습니다. 발표 자료는 회의 후 회사 웹사이트에 게시될 예정입니다.
Compass Therapeutics (Nasdaq: CMPX) a présenté des données précliniques sur CTX-10726, un anticorps bispéctif tetravalent ciblant PD-1 et VEGF-A, lors de la 40e réunion annuelle SITC le 7 novembre 2025.
Points clés : CTX-10726 a montré une haute affinité pour VEGF-A et PD-1 humains et cynomolgus, un blocage dépendant de la dose des interactions VEGF-A/VEGFR2 et PD-1/PD-L1, et une activité immunomodulatrice IFN-γ puissante in vitro. In vivo, CTX-10726 a entraîné l’élimination des tumeurs dans plusieurs modèles et a démontré une activité antitumorale supérieure à celle des anticorps de comparaison, y compris ivonescimab et bevacizumab, dans des modèles xéno-greffés et knock-in souris. L’entreprise a indiqué qu’une submission IND est en cours pour le T4 2025. Le matériel de présentation sera publié sur le site de l’entreprise après la réunion.
Compass Therapeutics (Nasdaq: CMPX) präsentierte präklinische Daten zu CTX-10726, einem tetravalenten bispezifischen Antikörper, der auf PD-1 und VEGF-A abzielt, auf der 40. SITC-Jahrestagung am 7. November 2025.
Wichtige Ergebnisse: CTX-10726 zeigte unaffine Bindung an VEGF-A und PD-1 beim Menschen und beim Cynomolgus; dosisabhängige Blockade der VEGF-A/VEGFR2- und PD-1/PD-L1-Interaktionen; sowie eine potente IFN-γ-immunmodulatorische Aktivität in vitro. In vivo führte CTX-10726 zur Tumoreliminierung in mehreren Modellen und zeigte eine überlegene antitumorale Aktivität gegenüber Vergleichsantikörpern einschließlich ivonescimab und Bevacizumab in Xenograft- und Knock-in-Mausmodellen. Das Unternehmen gab bekannt, dass ein IND-Antrag voraussichtlich im Q4 2025 gestellt wird. Präsentationsmaterialien werden nach der Sitzung auf der Website des Unternehmens veröffentlicht.
Compass Therapeutics (ناسداك: CMPX) قدمت بيانات ما قبل السريرية عن CTX-10726, وهو جسم مضاد ثنائي العصبيات رباعي القطب يستهدف PD-1 و VEGF-A, في الاجتماع السنوي الأربعين SITC في 7 نوفمبر 2025.
النتائج الرئيسية: أظهر CTX-10726 ارتبطية عالية بــ VEGF-A و PD-1 البشري وـ Cynomolgus، حجبًا يعتمد على الجرعة لتفاعلات VEGF-A/VEGFR2 وPD-1/PD-L1، ونشاطًا قويًا في تعديل المناعة عبر IFN-γ في المختبر. في الدراسات الحية، أدى CTX-10726 إلى القضاء على الأورام في عدة نماذج وأظهر نشاطًا مضادًا للأورام أعلى من الأجسام المضادة المقارنة بما في ذلك ivonescimab و bevacizumab في نماذج زينوجرافت وموشات نُخاعٍ مُدخَل. قالت الشركة إن تقديم IND في الطريق للربع الرابع من 2025. ستُنشر مواد العرض على موقع الشركة الإلكتروني بعد الاجتماع.
- Preclinical tumor elimination in multiple in vivo studies
- Superior anti-tumor activity versus ivonescimab in HCC827 and MC38hPD-L1 models
- Superior tumor-size reduction versus bevacizumab in MC38hPD-L1/hVEGF-A model
- High-affinity binding to human and cynomolgus VEGF-A and PD-1 in vitro
- IND submission on track for Q4 2025
- Results are limited to preclinical in vitro and animal models (no clinical efficacy yet)
- No human safety or clinical data reported to support translational outcomes
Insights
Preclinical data show dual PD-1/VEGF-A activity for CTX-10726 and an IND filing is on track in
Compass Therapeutics reports that CTX-10726 binds human and cynomolgus VEGF-A and PD-1 with high affinity, blocks VEGF-A/VEGFR2 and PD-1/PD-L1 interactions dose-dependently, and increases IFN-γ in vitro. In vivo, the program showed tumor regressions across multiple xenograft and knock-in models and reportedly outperformed named comparators including ivonescimab and bevacizumab in the specific models described. These facts describe a coherent mechanism: simultaneous angiogenesis inhibition and checkpoint blockade within one tetravalent bispecific molecule.
The main dependencies and risks are explicit in the data: every claim rests on preclinical models and head-to-head comparisons in mice and knock-in systems; translation to human safety, pharmacokinetics, and efficacy remains untested in humans per the disclosed content. The timeline hinge is the planned IND submission in
- CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies.
- In vivo, CTX-10726 outperformed select competitive antibodies in the class, including ivonescimab, in controlling tumor growth across multiple xenograft and syngeneic models.
- IND submission is on track for Q4 2025.
BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 5-9, 2025, in National Harbor, MD.
Details of the presentation are as follows:
Title: Preclinical Development of CTX-10726, a Tetravalent Bispecific Antibody Targeting PD-1 and VEGF-A for the Treatment of Patients with Cancer
Presenter: Diana Albu, PhD; Compass Therapeutics
Date & Time: November 7, 2025, from 12:15 PM-1:45 PM and 5:35-7:00 PM
Abstract number: 1151
Location: Gaylord National Resort & Convention Center – Exhibit Halls AB
Data highlights from the poster presentation include:
- In vitro, CTX-10726:
- Showed high-affinity binding to both human and cynomolgus monkey VEGF-A and PD-1;
- Effectively blocked VEGF-A/VEGFR2 and PD-1/PD-L1 interactions in a dose-dependent manner; and
- Demonstrated potent immunomodulatory activity as measured by IFN-γ production.
- In vivo, CTX-10726:
- Exhibited superior anti-tumor efficacy in a human lung cancer model in mice (HCC827 xenografts) compared to ivonescimab and an anti-VEGF-A antibody;
- Showed stronger anti-tumor activity against a human-PD-L1 expressing colon cancer cell line (MC38hPD-L1) implanted in human PD-1/PD-L1 double knock-in mice, compared with ivonescimab; and
- Demonstrated anti-tumor activity against human-PD-1 and VEGF-A expressing colon cancer cell line (MC38hPD-L1/hVEGF-A) implanted in human PD-1/PD-L1/VEGF-A triple knock-in mice, with significant reduction in tumor size compared with bevacizumab.
A copy of the presentation materials can be accessed on the Compass website at https://www.compasstherapeutics.com/pipeline/ once the presentation has concluded.
About CTX-10726
CTX-10726 is a bispecific, tetravalent antibody that simultaneously targets vascular endothelial growth factor (VEGF)-A and programmed cell death (PD)-1. CTX-10726 is being developed for the treatment of patients with metastatic or locally advanced tumor types where clinical checkpoint and angiogenesis signals are present. Checkpoint inhibitor antibody therapies targeting PD-1 and PD-L1 as well as agents targeting tumor angiogenesis have shown great success for the treatment of various malignancies. However, a substantial fraction of patients with PD-(L)1-positive tumors remain unresponsive to these therapies. CTX-10726 is believed to enhance anti-tumor response by both targeting immune checkpoints and tumor vasculature and has shown potent anti-tumor activity in preclinical mouse models. Currently, CTX-10726 is being tested in IND-enabling studies.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts.
Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding Compass’s product candidates, including the therapeutic potential of CTX-10726. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Compass’s ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, Compass’s ability to identify additional product candidates for development, Compass’s ability to develop, complete clinical trials for, obtain approvals for and commercialize any of its product candidates, competition in the industry in which Compass operates and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Compass files with the U.S. Securities and Exchange Commission (SEC) available at www.sec.gov, including without limitation Compass’s latest Annual Report on Form 10-K and subsequent filings with the SEC.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099
FAQ
What did Compass Therapeutics announce about CTX-10726 at SITC on November 7, 2025?
How does CTX-10726 (CMPX) compare to ivonescimab and bevacizumab in the presented preclinical data?
When is Compass planning an IND submission for CTX-10726 (CMPX)?
Did the SITC presentation include human clinical data for CTX-10726 (CMPX)?
Where can investors access Compass Therapeutics' CTX-10726 presentation materials after SITC 2025?
